Pathogenicity Genomic Island-Associated CrpP-Like Fluoroquinolone-Modifying Enzymes among Pseudomonas aeruginosa Clinical Isolates in Europe

José Manuel Ortiz de la Rosa; Patrice Nordmann; Laurent Poirel

doi:10.1128/AAC.00489-20

Pathogenicity Genomic Island-Associated CrpP-Like Fluoroquinolone-Modifying Enzymes among Pseudomonas aeruginosa Clinical Isolates in Europe

Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00489-20. doi: 10.1128/AAC.00489-20. Print 2020 Jun 23.

Authors

José Manuel Ortiz de la Rosa^{1

2}, Patrice Nordmann^{1

2

3

4}, Laurent Poirel^{5

2

4}

Affiliations

¹ Medical and Molecular Microbiology, Department of Medicine, Faculty of Science and Medicine, Fribourg, University of Fribourg, Switzerland.
² INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland.
³ Institute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland.
⁴ Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.
⁵ Medical and Molecular Microbiology, Department of Medicine, Faculty of Science and Medicine, Fribourg, University of Fribourg, Switzerland laurent.poirel@unifr.ch.

Abstract

Many transferable quinolone resistance mechanisms have been identified in Gram-negative bacteria. The plasmid-encoded 65-amino-acid-long ciprofloxacin-modifying enzyme CrpP was recently identified in Pseudomonas aeruginosa isolates. We analyzed a collection of 100 clonally unrelated and multidrug-resistant P. aeruginosa clinical isolates, among which 46 were positive for crpP-like genes, encoding five CrpP variants conferring variable levels of reduced susceptibility to fluoroquinolones. These crpP-like genes were chromosomally located as part of pathogenicity genomic islands.

Keywords: CrpP; Pseudomonas aeruginosa; ciprofloxacin; fluoroquinolones.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Drug Resistance, Bacterial
Europe
Fluoroquinolones* / pharmacology
Genomic Islands / genetics
Microbial Sensitivity Tests
Pseudomonas aeruginosa* / genetics
Virulence

Substances

Anti-Bacterial Agents
Fluoroquinolones